Navigation Links
Historic Agreement Reached to More Expertly and Efficiently Expand Proton Therapy Worldwide
Date:10/29/2007

Optivus Proton Therapy, Inc. Teams with Parsons Commercial Technology Group

Inc. to Produce Proton Beam Treatment Centers Globally

LOS ANGELES, Oct. 29 /PRNewswire/ -- Yesterday, at the 49th Annual Meeting of the American Society for Therapeutic Radiation Oncology (ASTRO), Optivus Proton Therapy, Inc. (Optivus(R)) and Parsons Commercial Technology Group Inc., a global business unit of Parsons Corporation, announced a historic teaming agreement has been formalized between the two companies to globally produce turn-key proton beam therapy centers.

"The agreement between the teams of Optivus and Parsons will assure our clients that their proton system will be completed on time by the most expert team in the field," said Jon Slater, Optivus President and CEO. "This is a win/win/win situation for Optivus, Parsons and our clients."

Founded in 1944, Parsons is one of the largest 100% employee-owned management, engineering, and construction companies in the United States.

"Parsons collaborates with innovators and leaders in many diversified markets. We are thrilled to add the development of proton beam therapy centers, with Optivus, to our wide-ranging portfolio," said John Small, Parsons Group President.

Optivus was formed by the engineers who designed and installed the world's first and most successful hospital-based proton center at Loma Linda University Medical Center in Loma Linda, California. The facility commissioned and maintained by Optivus has enjoyed more success than all other comparable competitors' systems, with higher throughput, the most patients treated, and the most types of diseases treated with the most reliable and efficient device on the market.

"Interest in the development of proton treatment centers has grown at an enormous rate in recent years and can largely be attributed to our successes," Slater said. "This development will further reinforce our position as the global leader in proton therapy technology," he added.

The Southern California-based Optivus Parsons team will meet the market demand for the development of proton therapy using Optivus' patented and proven technology.

"The global success and leadership of Parsons guarantees our ability to develop multiple proton centers simultaneously with a consistent level of resources and integrity," said Slater.

"The Optivus Parsons teaming agreement is a milestone for both companies," said Small. "We share Optivus' dedication and commitment to patients who will benefit from the life-saving proton treatment technology for which they've set the gold standard."

Representatives from Parsons will be in attendance at the Optivus booth 501 during ASTRO for Q & A.

ABOUT OPTIVUS AND PARSONS

Optivus Proton Therapy, Inc. is a pioneer in the field of proton therapy technology. Optivus' patented, FDA-cleared modular Proton Beam Therapy System (PBTS), the Conforma 3000(R), leads the industry in patient throughput, highest operational reliability and safety. To date, the Optivus system has delivered nearly half a million individual patient treatments with a perfect safety record. For more information about Optivus, visit http://www.optivus.com.

Parsons, celebrating more than 60 years of setting industry standards, is a leader in many diversified markets such as healthcare, education and public buildings, infrastructure, water, transportation, construction, planning, commercial, industrial manufacturing, communications, environmental, life sciences, critical facilities, nuclear and special materials, and homeland security. Parsons provides technical and management solutions to private industrial customers worldwide, as well as federal, regional, and local government agencies. For more information about Parsons, visit http://www.parsons.com.

Contact:

Lisa Pizzi

Marketing Communications

Optivus Proton Therapy, Inc.

909.799.8367 tel.

lpizzi@optivus.com

John Small

Parsons Group President

704.558.4124 tel.

john.small@parsons.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Optivus Proton Therapy, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
2. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
3. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
4. Number Of Babies Born Prematurely Nears Historic Half Million Mark In US
5. Historic trial for tuberculosis launched together by leading drug companies
6. Historic Increase In Incidence Of Sexually Transmitted Diseases In Scotland
7. Micro-world of Prehistoric Bacteria Found in Amber
8. Black-Owned Hospital Receives Historical Commemorative Marker
9. Agreement To Speed Up Development of Bird flu vaccine
10. MIOT Hospital Signs Agreement With German Healthcare Facility
11. Indo-Fiji Agreement in Field of Health, Medicine Approved
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... choose a modern procedure that achieves results in a fraction of the time ... Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary treatment with ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers of America ... a reputable physician in their area, announces the launch of a new and proprietary ... who are looking for reputable physicians to help them with back or neck pain ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
(Date:4/25/2017)... ... 2017 , ... Vetoquinol USA® , a world-class developer ... of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. ... level. , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the ... CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed tablet in ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... PARIS , April 20, 2017 ... EyeCET platform, the first non-viral gene expression technology that ... in the eye to address a wide range of ... UK Medicines and Healthcare products Regulatory Agency (MHRA) to ... ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
Breaking Medicine Technology: